Opportunity and challenges of nasal powders: Drug formulation and delivery

Tiozzo Fasiolo, L; Manniello, MD; Tratta, E; Buttini, F; Rossi, A; Sonvico, F; Bortolotti, F; Russo, P; Colombo, G

Opportunity and challenges of nasal powders: Drug formulation and delivery

Tiozzo Fasiolo, L Manniello, MD Tratta, E Buttini, F Rossi, A Sonvico, F

Bortolotti, F Russo, P Colombo, G

Permalink

Publication Type:: Journal Article
Citation:: European Journal of Pharmaceutical Sciences, 2018, 113 pp. 2 - 17
Issue Date:: 2018-02-15

Closed Access

	Filename	Description	Size
	1-s2.0-S0928098717305195-main.pdf	Published Version	1.59 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Tiozzo Fasiolo, L	en_US
dc.contributor.author	Manniello, MD	en_US
dc.contributor.author	Tratta, E	en_US
dc.contributor.author	Buttini, F	en_US
dc.contributor.author	Rossi, A	en_US
dc.contributor.author	Sonvico, F https://orcid.org/0000-0001-7372-1456	en_US
dc.contributor.author	Bortolotti, F	en_US
dc.contributor.author	Russo, P	en_US
dc.contributor.author	Colombo, G	en_US
dc.date.available	2017-09-18	en_US
dc.date.issued	2018-02-15	en_US
dc.identifier.citation	European Journal of Pharmaceutical Sciences, 2018, 113 pp. 2 - 17	en_US
dc.identifier.issn	0928-0987	en_US
dc.identifier.uri	http://hdl.handle.net/10453/128325
dc.description.abstract	© 2017 Elsevier B.V. In the field of nasal drug delivery, among the preparations defined by the European Pharmacopoeia, nasal powders facilitate the formulation of poorly water-soluble active compounds. They often display a simple composition in excipients (if any), allow for the administration of larger drug doses and enhance drug diffusion and absorption across the mucosa, improving bioavailability compared to nasal liquids. Despite the positive features, however, nasal products in this form still struggle to enter the market: the few available on the market are Onzetra Xsail® (sumatriptan) for migraine relief and, for the treatment of rhinitis, Rhinocort® Turbuhaler® (budesonide), Teijin Rhinocort® (beclomethasone dipropionate) and Erizas® (dexamethasone cipecilate). Hence, this review tries to understand why nasal powder formulations are still less common than liquid ones by analyzing whether this depends on the lack of (i) real evidence of superior therapeutic benefit of powders, (ii) therapeutic and/or commercial interest, (iii) efficient manufacturing methods or (iv) availability of suitable and affordable delivery devices. To this purpose, the reader's attention will be guided through nasal powder formulation strategies and manufacturing techniques, eventually giving up-to-date evidences of therapeutic efficacy in vivo. Advancements in the technology of insufflation devices will also be provided as nasal drug products are typical drug-device combinations.	en_US
dc.relation.ispartof	European Journal of Pharmaceutical Sciences	en_US
dc.relation.isbasedon	10.1016/j.ejps.2017.09.027	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Mucous Membrane	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Rhinitis	en_US
dc.subject.mesh	Water	en_US
dc.subject.mesh	Beclomethasone	en_US
dc.subject.mesh	Dexamethasone	en_US
dc.subject.mesh	Budesonide	en_US
dc.subject.mesh	Drug Carriers	en_US
dc.subject.mesh	Powders	en_US
dc.subject.mesh	Excipients	en_US
dc.subject.mesh	Administration, Intranasal	en_US
dc.subject.mesh	Equipment and Supplies	en_US
dc.subject.mesh	Biological Availability	en_US
dc.subject.mesh	Chemistry, Pharmaceutical	en_US
dc.subject.mesh	Permeability	en_US
dc.subject.mesh	Solubility	en_US
dc.subject.mesh	Drug Liberation	en_US
dc.subject.mesh	Nasal Absorption	en_US
dc.title	Opportunity and challenges of nasal powders: Drug formulation and delivery	en_US
dc.type	Journal Article
utslib.citation.volume	113	en_US
utslib.for	1115 Pharmacology and Pharmaceutical Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	113	en_US

Abstract:

© 2017 Elsevier B.V. In the field of nasal drug delivery, among the preparations defined by the European Pharmacopoeia, nasal powders facilitate the formulation of poorly water-soluble active compounds. They often display a simple composition in excipients (if any), allow for the administration of larger drug doses and enhance drug diffusion and absorption across the mucosa, improving bioavailability compared to nasal liquids. Despite the positive features, however, nasal products in this form still struggle to enter the market: the few available on the market are Onzetra Xsail® (sumatriptan) for migraine relief and, for the treatment of rhinitis, Rhinocort® Turbuhaler® (budesonide), Teijin Rhinocort® (beclomethasone dipropionate) and Erizas® (dexamethasone cipecilate). Hence, this review tries to understand why nasal powder formulations are still less common than liquid ones by analyzing whether this depends on the lack of (i) real evidence of superior therapeutic benefit of powders, (ii) therapeutic and/or commercial interest, (iii) efficient manufacturing methods or (iv) availability of suitable and affordable delivery devices. To this purpose, the reader's attention will be guided through nasal powder formulation strategies and manufacturing techniques, eventually giving up-to-date evidences of therapeutic efficacy in vivo. Advancements in the technology of insufflation devices will also be provided as nasal drug products are typical drug-device combinations.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/128325